Summary
Edwards Lifesciences Corporation (EW) reported its third-quarter and nine-month results for the period ending September 30, 2007. The company demonstrated solid top-line growth, with total net sales increasing by 5.7% to $261.4 million for the quarter and 3.5% to $798.1 million for the nine months, year-over-year. This growth was primarily driven by strong performance in the Critical Care and Vascular segments, with notable contributions from the FloTrac system and LifeStent products. Profitability showed mixed results. While gross profit margin improved slightly, driven by a favorable product mix and foreign currency impacts, operating expenses, particularly SG&A and R&D, increased due to strategic investments in new product launches and pipeline development, including the Edwards SAPIEN Transcatheter Heart Valve (THV) in Europe and the PARTNER trial. Net income for the quarter was $29.1 million, a modest increase from $27.8 million in the prior year, but diluted earnings per share decreased slightly to $0.48 from $0.51, reflecting the increased share count and higher expenses. The company also completed a $150 million convertible debt offering during the quarter, reclassifying it as a current liability due to its near-term redemption option for holders.
Key Highlights
- 1Net sales increased by 5.7% to $261.4 million in Q3 2007 and by 3.5% to $798.1 million for the first nine months of 2007 compared to the same periods in 2006.
- 2Critical Care and Vascular product lines showed significant growth, with Critical Care sales up 13.7% quarterly and 11.4% year-to-date, and Vascular sales up 27.3% quarterly and 18.2% year-to-date.
- 3Gross profit margin improved to 65.3% in Q3 2007 from 64.7% in Q3 2006, benefiting from a favorable product mix and foreign currency impacts.
- 4Research and Development expenses increased by $2.8 million in the quarter and $4.6 million year-to-date, reflecting investments in transcatheter valve and Critical Care programs, including the PARTNER trial.
- 5Selling, General, and Administrative (SG&A) expenses increased by $11.5 million in the quarter and $22.6 million year-to-date, driven by investments for the Edwards SAPIEN THV launch and higher sales-related spending.
- 6The company issued $150 million in convertible senior debentures, which are now classified as a current liability due to the May 2008 put option.
- 7Edwards Lifesciences ended the quarter with $175.7 million in cash and cash equivalents and continued its share repurchase program, announcing a new $250 million authorization.